梅特福尔在肝脏疾病中的进展
Jiaqi Bao1, Yudi Zhao1, Xiao Xu1,2
1The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Current medicinal chemistry
|February 1, 2024
概括
甲福明是一种糖尿病药物,通过激活AMPK,在治疗肝病方面表现有前途. 它有助于减少肝损伤,脂肪肝疾病和癌症风险.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 甲胺是一种广泛使用的2型糖尿病药物,以其安全性和可负担性而闻名.
- 新兴研究揭示了超出血糖控制的多种药理学效应.
- 肝脏疾病代表着一个重要的全球健康负担,有未满足的治疗需求.
研究的目的:
- 审查最近关于甲福明在治疗各种肝脏疾病中的应用的研究.
- 阐明甲胺对肝脏的保护作用背后的分子机制.
- 评估甲福明作为治疗肝病的治疗剂的潜力.
主要方法:
- 对调查甲福明对肝脏健康影响的临床前和临床研究的综述.
- 对分子通路的分析,包括AMPK激活和线粒体复合体1抑制.
- 检查甲福明对脂质代谢,炎症和肝脏癌症进展的影响.
主要成果:
- 甲胺通过线粒体复合体1抑制 (高剂量) 或溶酶体通路 (低剂量) 激活AMP激活蛋白激酶 (AMPK).
- 激活的AMPK减少脂肪酸合成,抑制瘤生长和转移,并调节瘤微环境.
- 甲胺减轻反应性氧物种 (ROS) 的产生,从而减少肝损伤,缓解非酒精性脂肪肝病和肝硬化等疾病.
- 研究表明,甲福明可能会降低肝细胞癌和胆管癌的发病率.
结论:
- 甲福明在减轻肝损伤和治疗非酒精性脂肪肝病和肝硬化方面显示出显著的潜力.
- 药物抑制瘤增殖和减少ROS的能力表明它在预防肝癌方面发挥了作用.
- 甲胺为预防和治疗各种肝病提供了一个有前途的新途径.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
175
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
175
01:23Dipeptidyl Peptidase 4 Inhibitors
187
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
187
01:06Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
01:30Liver Physiology
554
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
554
01:11Renal Failure: Dose Adjustments
89
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
89